Examination of efficacy and safety treated by romosozumab or denosumab in osteoporosis with collagen disease including glucocorticoid-induced osteoporosis

Examination of efficacy and safety treated by romosozumab or denosumab in osteoporosis with collagen disease including glucocorticoid-induced osteoporosis - Efficacy and safety treated by romosozumab or denosumab in osteoporosis with collagen disease including GIO

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036837

Enrollment

Registered

2019-05-25

Start date

2019-05-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis with collagen disease including glucocorticoid-induced osteoporosis

Interventions

romosozumab plus active vitamin D group denosumab plus active vitamin D group

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1:Osteoporosis patients with collagen disease over 20 years old 2:GIO patients over 20 years old 3:Patients who agree with this study

Exclusion criteria

Exclusion criteria: 1:Patients who have taken romosozumab or denosumab before 2:Patients who are allergic to romosozumab or denosumab or eldecalcitol 3:Hypocalcemia 4:Pregnant or breast-feeding patients 5:Patients with severe renal function (eGFR 30 ml / min / 1.73 m2) or patients undergoing dialysis 6:Patients at risk of hypercalcemia (patients with renal dysfunction, patients with malignancy, patients with primary hyperparathyroidism) 7:Patients with severe liver dysfunction 8:Patients with urolithiasis and patients with a history of their history 9:Others, patients judged by the research director as inappropriate

Design outcomes

Primary

Measure	Time frame
Bone mineral density at 12 months after treatment	—

Secondary

Measure	Time frame
Occurrence of hypocalcemia	—

Countries

Japan

Contacts

Public ContactYukio Nakamura

Shinshu University School of Medicine Dept. of Orthopaedic Surgery

yxn14@aol.jp0263372659

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026